
Opinion|Videos|November 6, 2025
Managing Adverse Events and Integrating Amivantamab Plus Lazertinib
Panelists discuss how proactive AE management optimizes safety and adherence with emerging EGFR-targeted regimens.
Advertisement
Episodes in this series

Panelists discuss how effective management of adverse events (AEs) supports successful integration of novel EGFR-targeted combinations like amivantamab and lazertinib. They review toxicity profiles across therapies, noting dermatologic and infusion-related reactions as common concerns. Strategies such as early recognition, prophylactic care, and multidisciplinary support are highlighted for minimizing discontinuation rates and maintaining adherence. The discussion emphasizes that proactive AE management enhances tolerability and patient confidence, ensuring long-term therapy success.
Advertisement
Related to this article

Merck has begun the phase 3 ENHANCE-3 trial testing whether ensifentrine added to standard of care prevents COPD exacerbations in high-risk adults.

Non-CF bronchiectasis prevalence rose across commercial, Medicare, and Medicaid plans from 2016 to 2024, while incidence stayed relatively stable.

Shorter telomere length was linked to a usual interstitial pneumonia pattern (UIP) on CT in patients with ILD, per research presented at CHEST 2026.

Low awareness that fatty liver can silently progress and that MASH fibrosis is treatable drives missed follow-up testing, says Rohit Loomba, MD.

The FDA approved asundexian (Sunharbo) with antiplatelet therapy to reduce recurrent stroke risk after noncardioembolic stroke or high-risk TIA.
Advertisement
Advertisement
Trending on AJMC
1
ObesityWeek 2026: Studies Map GLP-1 Access Gaps, Obesity's Costs
2
FDA Approves Durvalumab Plus EV Before Surgery in Cisplatin-Ineligible MIBC
3
MM’s Vulnerability to CAR T Was a Happy Surprise: Nikhil C. Munshi, MD
4
Payers, Eosinophil Thresholds Shape Who Gets a COPD Biologic
5

